1985606-14-1

Basic information

• Product Name: Baloxavir marboxil
• Synonyms: Baloxavir marboxil;baloxavir marboxil S-033188
• CAS NO: 1985606-14-1
• Molecular Formula: C27H23F2N3O7S
• Molecular Weight: 571.55
• EINECS: -0
• Product Categories: API
• Mol File: 1985606-14-1.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 712.8±70.0 °C(Predicted)
• Appearance: /
• Density: 1.57±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: -1.46±0.40(Predicted)
• CAS DataBase Reference: Baloxavir marboxil(CAS DataBase Reference)
• NIST Chemistry Reference: Baloxavir marboxil(1985606-14-1)
• EPA Substance Registry System: Baloxavir marboxil(1985606-14-1)

Safety Data

• Hazardous Substances Data: 1985606-14-1(Hazardous Substances Data)

Usage

Description

Baloxavir marboxil is an antiviral drug developed by Shionogi Co., a Japanese pharmaceutical company and Roche for the treatment of influenza A and influenza B infections. The drug was initially approved for use in Japan in February 2018 and approved by the FDA on October 24, 2018 for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours Label. Baloxavir marboxil, a cap-endonuclease inhibitor, has a unique mechanism of action when compared to the currently existing neuraminidase inhibitor drug class used to treat influenza infections.

Pharmacokinetics

Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease which prevents polymerase function and therefore influenza virus mRNA replication 5, 3. It has shown therapeutic activity against influenza A and B virus infections, including strains resistant to current antiviral agents 1. This drug inhibits an enzyme required for viral replication, thus rapidly treating flu virus infection 5, Label and alleviating the symptoms associated with infection. A single dose of this agent was shown to be superior to placebo in relieving influenza symptoms and superior to both oseltamivir and placebo drug in virologic outcomes (marked by decreased viral load).

Uses

Different sources of media describe the Uses of 1985606-14-1 differently. You can refer to the following data:
1. Baloxavir marboxil is an influenza medication, an antiviral,that is taken as a single dose tablet,by mouth, by individuals that are 12 years of age or older,that have presented symptoms of this infection for no more than 48 hours.The efficacy of baloxavir marboxil administered after 48 hours has not been tested.
2. Baloxavir Marboxil is a prodrug of S-033447, which is an inhibitor of the cap-dependent endonuclease of influenza A and B viruses.

Contraindications

Baloxavir marboxil should not be co-administered with dairy products, calcium-fortified beverages, or laxatives, antacids, or oral supplements containing calcium, iron, magnesium, selenium, aluminum or zinc.

Metabolism

Baloxavir marboxil is a prodrug that is converted by hydrolysis to baloxavir, the active form that exerts anti-influenza virus activity Label.

Mechanism of action

Baloxavir marboxil is an influenza therapeutic agent, specifically, an enzyme inhibitor targeting the influenza virus' cap-dependent endonuclease activity, one of the activities of the virus polymerase complex. In particular, it inhibits a process known as cap snatching, by which the virus derives short, capped primers from host cell RNA transcripts, which it then uses for polymerase-catalyzed synthesis of its needed viral mRNAs. A polymerase subunit binds to the host pre-mRNAs at their 5' caps, then the polymerase's endonuclease activity catalyzes its cleavage "after 10–13 nucleotides". As such, its mechanism is distinct from neuraminidase inhibitors such as oseltamivir and zanamivir.

Side effects

Common side effects following the single dose administration of baloxavir marboxil include diarrhea, bronchitis, common cold, headache, and nausea. Adverse events were reported in 21% of people who received baloxavir, 25% of those receiving placebo, and 25% of oseltamivir.